IL2 and type 1 diabetes mellitus: Our study demonstrates a reduction of circulatory IL-2 in pSS patients and accompanied with enhanced Th17 generation, which is consistent with previous reports that reduced IL-2 availability in SLE and type I diabetes patients (32, 33).